Clindamycin Phosphate-D5w (clindamycin phosphate/dextrose 5 % in water)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Clindamycin, a lincosamide antibiotic, is a derivative of lincomycin.
Clindamycin is used for the treatment of certain serious infections caused by susceptible aerobic gram-positive bacteria (staphylococci, streptococci, pneumococci) and for the treatment of certain serious infections caused by susceptible anaerobic bacteria. Use of clindamycin generally should be reserved for the treatment of serious infections when less toxic anti-infectives cannot be used (e.g., penicillin-allergic patients or other patients for whom a penicillin is inappropriate). Because clindamycin has been associated with potentially fatal colitis (see Cautions: GI Effects), the manufacturer recommends that clinicians consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Generic name: clindamycin phosphate/dextrose 5 % in water
Pronunciation: (KLIN-da-MYE-sin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Clindamycin Phosphate-D5w
Indications
The following indications are listed for Clindamycin Phosphate-D5w:
- Anaerobic Endometritis
- Anaerobic Joint Infection
- Anaerobic Lung Abscess
- Anaerobic Pelvic Cellulitis
- Anaerobic Peritonitis
- Anaerobic Pneumonia
- Anaerobic Tubo-Ovarian Abscess
- Clostridium Perfringens Empyema
- Gas Gangrene Caused By Clostridium Perfringens
- Intra-Abdominal Anaerobic Abscess
- Pneumococcal Pneumonia
- Postsurgical Vaginal Cuff Anaerobic Infections
- Sepsis Caused By Anaerobic Bacteria
- Skin And Skin Structure Anaerobic Infection
- Skin And Skin Structure Streptococcus Pyogenes Infection
- Staphylococcal Pneumonia
- Staphylococcal Septicemia
- Staphylococcus Aureus Osteomyelitis
- Staphylococcus Aureus Skin And Skin Structure Infection
- Streptococcal Pneumonia
- Streptococcal Septicemia
Also known as: Abdominal Abscess Due To Anaerobic Bacteria, Anaerobic Sepsis, Clostridium Perfringens Gas Gangrene, Empyema Due To Clostridium Perfringens, Endometritis Due To Anaerobic Bacteria, Gas Gangrene Due To Clostridium Perfringens, Infection Of The Lungs Due To Anaerobic Bacteria, Joint Infection Due To Anaerobic Bacteria, Lung Abscess Due To Anaerobic Bacteria, Osteomyelitis Due To Staphylococcus Aureus, Osteomyelitis Due To Staphylococcus Pyogenes Aureus, Parametritis Due To Anaerobic Bacteria, Pelvic Cellulitis Due To Anaerobic Bacteria, Peritonitis Due To Anaerobic Bacteria, Pneumonia Due To Staphylococcus Species, Pneumonia Due To Staphylococcus Spp., Pneumonia Due To Streptococcus Pneumoniae, Pneumonia Due To Streptococcus Species, Pneumonia Due To Streptococcus Spp., Postsurgical Anaerobic Vaginal Cuff Infection, Pyogenic Bone Infection Due To Staphylococcus Aureus, Pyothorax Due To Clostridium Perfringens, Septicemia Due To Staphylococcus Species, Septicemia Due To Staphylococcus Spp., Skin & Skin Soft Tissue Streptococcus Pyogenes Infection, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Staphylococcal Sepsis, Streptococcal Sepsis, Tubo-Ovarian Abscess Due To Anaerobic Bacteria.
Dosing
Dosage of clindamycin hydrochloride, clindamycin palmitate hydrochloride, and clindamycin phosphate is expressed in terms of clindamycin.
Dosage and duration of treatment depend on the severity of the infection. If clindamycin is used in infections caused by Streptococcus pyogenes (group A beta-hemolytic streptococci; GAS), therapy should be continued for at least 10 days. At least 6 weeks of therapy may be required for certain serious infections (e.g., osteomyelitis).
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats and mice using oral or parenteral dosages of clindamycin up to 600 mg/kg daily (3.2 and 1.6 times, respectively, the maximum recommended human oral dosage or 2.1 and 1.1 times, respectively, the maximum recommended human parenteral dosage on a mg/m2 basis) have not revealed evidence of teratogenicity.
In clinical trials that included pregnant women, systemic clindamycin administered during the second and third trimesters was not associated with an increased frequency of congenital abnormalities. There are no adequate and well-controlled studies to date using clindamycin in pregnant women during the first trimester of pregnancy. Because animal reproduction studies are not always predictive of human response, clindamycin should be used during pregnancy only when clearly needed.
Clindamycin phosphate injection contains benzyl alcohol as a preservative; benzyl alcohol can cross the placenta. (See Cautions: Pediatric Precautions.)
Clindamycin is distributed into milk (see Pharmacokinetics: Distribution), and has the potential to cause adverse effects on the GI flora of breast-fed infants.
The manufacturer states that use of oral or IV clindamycin in the mother is not a reason to discontinue breast-feeding; however, it may be preferable to use an alternate anti-infective. If clindamycin is used in a breast-feeding mother, the infant should be monitored for possible adverse effects on GI flora, including diarrhea and candidiasis (thrush, diaper rash) or, rarely, blood in the stool indicating possible antibiotic-associated colitis. The benefits of breast-feeding and the importance of clindamycin to the woman should be considered along with potential adverse effects on the breast-fed child from the drug or from the underlying maternal condition.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.